Lactollin

β-Lactolin (Lactollin): A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

β-Lactolin — also encountered in the scientific literature under the designation Lactollin — is a bioactive lacto-tetrapeptide with the amino acid sequence glycine–threonine–tryptophan–tyrosine, abbreviated in single-letter notation as GTWY. A recent study identified β-lactolin, a β-lactoglobulin-derived Gly-Thr-Trp-Tyr tetrapeptide, which improves memory impairment in a pharmacologically-induced amnesia mouse model. It belongs to a broader class of tryptophan–tyrosine (WY)-related β-lactopeptides found in dairy. β-Lactolin belongs to the Trp-Tyr-related β-lactopeptide family, which also improve memory impairment and are abundant in Camembert and other types of cheeses fermented by Penicillium.

The parent protein from which β-lactolin is liberated is β-lactoglobulin, the dominant whey protein in bovine (cow's) milk. Researchers identified tryptophan-tyrosine (WY)-related peptides, including the β-lactopeptide of glycine-threonine-tryptophan-tyrosine (GTWY), β-lactolin, derived from β-lactoglobulin in whey proteins digested by specific enzymes. The tetrapeptide is released during proteolytic digestion — either by microbial enzymes active during cheese fermentation, or by exogenous food-grade enzymes applied industrially to whey protein. Researchers previously identified tryptophan–tyrosine (WY)-related peptides including glycine–threonine–tryptophan–tyrosine, designated as β-lactolin, released from β-lactoglobulin in whey protein. WY-related peptides, including β-lactolin, are abundant in fermented dairy products such as camembert cheese and are richly released from whey protein digestion with specific enzymes.

As a tetrapeptide, β-lactolin has a relatively low molecular weight, consistent with the general class of bioactive milk-derived peptides. Its name reflects its origin: lacto- for its dairy source, and the -lin suffix as a conventional naming convention for small bioactive peptides. In supplement contexts, it is supplied not as a free peptide in isolation but as a standardized whey peptide digest enriched in β-lactolin (also called GTWY-rich whey peptide or β-lactolin-rich whey peptide). A whey digest produced by specific enzymes is rich in β-lactolin, which also reduces spatial memory impairment.

2. Natural Sources and Occurrence in Food

β-Lactolin is found in the natural food supply within certain dairy products. Its concentration in any given food depends on the extent of protein fermentation or hydrolysis.

• Camembert cheese and Penicillium-fermented cheeses: β-Lactolin is rich in Camembert cheese and other cheeses fermented by Penicillium. The mold-ripening process releases WY-containing peptides from β-lactoglobulin, making these cheeses a natural dietary source.
• Whey protein derived from yogurt and cheese production: Whey proteins are abundant in supernatants of yogurt and are byproducts of cheese. Enzymatic digestion of these whey proteins yields β-lactolin among other bioactive peptides.
• General fermented dairy products: Accumulating epidemiological and clinical studies indicate that intake of fermented dairy products rich in β-lactolin improves memory retrieval and executive function and attenuates cognitive decline in the elderly.

The broader epidemiological context is relevant: Epidemiological studies show that consumption of dairy products reduces the risk for cognitive decline and dementia in the elderly. Researchers have proposed that β-lactolin and related WY peptides in fermented dairy represent the active constituents responsible for at least part of this observed protective association.

3. Common Forms and Preparations

In research and supplement contexts, β-lactolin is administered as a standardized whey peptide preparation — a digest of whey protein that has been enriched in the GTWY tetrapeptide through controlled enzymatic hydrolysis. This form is used in all published clinical trials. In a randomized, double-blind, placebo-controlled trial, researchers evaluated the effects of daily supplements with whey peptide containing 1.6 mg of GTWY, β-lactolin, on cognitive functions in healthy older adults. Clinical studies have delivered the compound orally in tablet form. No intravenous, transdermal, or other non-oral delivery forms have been reported in the published human literature. The whey peptide preparation is produced industrially, primarily by Kirin Holdings Co. (Japan), which has sponsored most of the clinical research to date. Current studies were funded by Kirin Holdings Co.

4. Traditional and Historical Use

β-Lactolin as a defined molecular entity was identified only in the modern era of peptide biochemistry and was not known as a discrete compound in traditional medicine. There is no documented traditional use of β-lactolin per se in any herbal, Ayurvedic, Traditional Chinese Medicine, or other historical medical system.

However, its parent matrix — fermented dairy, and particularly ripened cheeses — has a long culinary and nutritional history in European culture, with Camembert-style cheeses dating to at least the 18th century in Normandy, France. The nutritional or health properties attributed historically to aged dairy products were not specifically connected to β-lactolin in any traditional written record. The compound's isolation, characterization, and biological investigation represent an entirely modern scientific endeavor, arising from late 20th- and early 21st-century interest in bioactive milk peptides.

In fermented dairy products, a variety of fatty acids or peptides are released during the fermentation process, and these compounds have been shown to exhibit various functions, including psychiatric functions. The specific identification of β-lactolin as a distinct, orally bioavailable, brain-penetrant tetrapeptide emerged from Japanese academic and industry research in the 2010s.

5. Key Constituents and Established Mechanisms of Action

5.1 Monoamine Oxidase B (MAO-B) Inhibition

The primary and best-characterized mechanism of β-lactolin is inhibition of the enzyme monoamine oxidase B (MAO-B). The main enzymes responsible for dopamine (DA) metabolism are monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT), both of which are highly expressed in astrocytes. MAO-B inhibitors are widely used for the treatment of Parkinson's disease, since MAO-B inhibition increases the synaptic DA concentration. Recent studies have demonstrated that some MAO-B inhibitors have preventive and therapeutic effects on the development of Alzheimer's disease.

β-Lactolin orally administered can enter the brain and inhibit the activity of monoamine oxidase B (MAO-B), thereby resulting in increased dopamine levels in the brain in normal ICR mice, and dopamine D1-like receptor is involved in the memory improvement induced by β-lactolin in scopolamine-induced amnesia model mice.

The MAO-B inhibitory activity also has implications for reactive oxygen species (ROS) production in brain tissue. MAO-B is known to be an important source of ROS in astrocytes, because it generates hydrogen peroxide (H₂O₂) during enzymatic reactions. Several studies have shown that H₂O₂ production in reactive astrocytes is increased in an MAO-B-dependent manner and an MAO-B inhibitor suppressed ROS production and neuronal loss in transgenic mouse models of Alzheimer's disease and Parkinson's disease. Recently, food-derived MAO-B inhibitory peptides have been identified.

5.2 Dopaminergic System Activation

Through MAO-B inhibition, β-lactolin elevates dopamine concentrations in critical brain regions. In vivo microdialysis revealed that oral administration of β-lactolin increased the extracellular concentration of dopamine in the hippocampus and enhanced both spatial working memory, as measured in the Y-maze test, and spatial reference memory, as measured in the novel object location test. Downstream activation of dopamine D1 receptors is required for the memory-enhancing effects: The memory-enhancing effects of β-lactolin, but not the baseline memory functions, were impaired by the knockdown of the dopamine D1 receptor subtype in the hippocampus.

Dopamine D1-like receptor activation is also implicated in the antidepressant-like activity observed in rodent models: The administration of β-lactolin improved depression-like behavior of rodents, as assessed in the tail suspension test, which was inhibited by the inhibition of dopamine D1-like receptor.

5.3 Anti-neuroinflammatory Effects

In transgenic Alzheimer's disease mouse models, β-lactolin demonstrated broad anti-neuroinflammatory activity: Intake of β-lactolin and whey digestion rich in β-lactolin reduced the levels of inflammatory cytokines, suppressed the infiltration of activated microglia, decreased the levels of amyloid-β, ameliorated impaired long-term object memory, and attenuated decreased synaptophysin, dopamine, brain-derived neurotrophic factor, and insulin-like growth factor 1 levels in the cortex in 5×FAD transgenic mice.

The proposed mechanistic link between MAO-B inhibition and neuroinflammation suppression involves dopamine-mediated regulation: Researchers speculated that MAO-B-inhibiting activity of β-lactolin increases the level of dopamine, thereby resulting in the suppression of inflammation and Aβ production; however, further studies are needed to confirm the effects of β-lactolin on microglia activation and Aβ production in vitro systems.

5.4 Effects on Cerebral Blood Flow and Neural Activity

In human studies, β-lactolin has been shown to increase cerebral blood flow (CBF) in prefrontal regions: The changes in oxy-Hb in CH23 located at the left dorsolateral prefrontal cortex (DLPFC) during the spatial working memory task showed a higher statistical significance in the β-lactolin group than in the placebo group. The CBF changes in CH23 were correlated with the reaction time for the working memory task. β-Lactolin supplementation increases CBF in the DLPFC area, which contributes to improved cognitive functions.

5.5 Monoamine System and Mood Regulation

WY-related peptides improve spatial working and episodic memory via the inhibition of monoamine oxidase-B and the subsequent increase in dopamine levels in the brain and activation of dopamine D1-like receptors in rodents. Whey-derived β-lactolin (glycine–threonine–tryptophan–tyrosine tetrapeptide) activates dopaminergic systems and improves psychiatric function in rodents.

6. Body Systems and Health Areas of Association

• Central Nervous System / Cognitive Function — primary area of research; memory, attention, executive function.
• Neuroinflammation and Neurodegeneration — amyloid-β, microglia, tau-related pathology in animal models.
• Mood and Psychiatric Health — anxiety, stress, depression-like behavior.
• Cerebrovascular Function — prefrontal cortex cerebral blood flow during cognitive tasks.

7. Scientific Evidence by Area of Use

7.1 Cognitive Function in Healthy Older Adults

Human / Clinical Evidence

The strongest and most replicated human evidence concerns cognitive function in middle-aged to older healthy adults. Multiple randomized, double-blind, placebo-controlled trials (RCTs) have been published.

Key RCT — cognitive performance in older adults (2019): 114 healthy subjects aged 50–75 were supplemented with the whey peptide or placebo for 12 weeks, and changes in cognitive function were assessed using neuropsychological tests at weeks 0, 6, and 12 of the intervention. Supplementation with whey peptides richly containing β-lactolin (1.6 mg/day) for 6 and 12 weeks improved memory, attention, and executive functions associated with the function of the dorsolateral prefrontal cortex in middle-aged adults (45–64 years old) with high subjective fatigue. In another clinical trial, researchers showed that supplementation with β-lactolin-rich whey peptide in healthy subjects aged 50–75 years for 12 weeks enhanced cognitive performance, such as associative learning.

Integrated / Meta-analytic evidence: Three randomized controlled trials evaluating the effect of β-lactolin on memory in healthy adults were selected for integrated analysis. The results showed that the score of cued recall among the neuropsychological tests in the β-lactolin group was significantly higher than that in the placebo group (g=0.33; 95% CI: 0.10, 0.55). In addition, the total memory score was higher but this difference was not significant (g=0.17; 95% CI: −0.09, 0.43). These results suggest that supplementation with β-lactolin improves cued recall in healthy older adults.

EEG / Neural activity RCT: In a randomized, double-blind, placebo-controlled study, 30 participants (45–64 years old) consumed β-lactolin or placebo for 6 weeks. Neural activity during auditory and language tasks was measured through 64-channel electroencephalography. Moreover, verbal fluency tests were performed at baseline and after 6 weeks. β-Lactolin supplementation improves attention, executive function, and memory retrieval.

Cerebral blood flow RCT: Researchers examined the effects of β-lactolin on cerebral blood flow (CBF) using near-infrared spectroscopy (NIRS) in a placebo-controlled randomized double-blind study. Fifty healthy participants (45–60 years old) were randomly allocated to the β-lactolin and placebo groups and supplemented for 6 weeks.

Strength of evidence: The cognitive evidence in healthy adults is supported by multiple industry-sponsored RCTs conducted primarily in Japanese populations. Effect sizes are modest (e.g., cued recall Hedges' g = 0.33). Independent replication by researchers outside Kirin Holdings is limited, and most studies enrolled relatively small samples. The evidence is promising but not yet sufficient to establish a health claim under regulatory frameworks such as the European Food Safety Authority (EFSA) or the U.S. FDA.

7.2 Mild Cognitive Impairment (MCI)

Clinical trial in MCI: This study aimed to investigate the effects of a long-term intervention with β-lactolin, a tetrapeptide derived from milk, on cognitive performance in individuals with mild cognitive impairment (MCI). A randomized, double-blind, placebo-controlled trial was conducted. Researchers recruited 48 participants aged 50 years or older with a Clinical Dementia Rating (CDR) score of 0.5. Participants were administered β-lactolin (1.8 mg daily) or placebo for 24 weeks.

In the intra-group comparison of the MoCA-J delayed recall score, a significant difference was observed in the β-lactolin group after 12 and 24 weeks of intervention. Furthermore, the subgroup analysis stratified for females only showed a significant difference in MoCA-J total score in the β-lactolin group after 24 weeks of intervention. β-Lactolin intake does not significantly improve cognitive function in MCI in an inter-group comparison; nevertheless, the MoCA-J delayed recall score was significantly improved in the β-lactolin group. The number of participants was lower than planned, limiting the confirmation of the effectiveness of β-lactolin on MCI.

Strength of evidence: Preliminary and underpowered. The MCI trial did not meet its primary endpoint in a between-group comparison. Evidence in this population cannot be considered established.

7.3 Alzheimer's Disease Pathology

Preclinical Evidence Only

Researchers examined the effects of β-lactolin and whey digestion rich in β-lactolin on AD pathology in 5×FAD transgenic mice and PS19 tauopathy mice. Intake of β-lactolin and whey digestion rich in β-lactolin reduced the levels of inflammatory cytokines, suppressed the infiltration of activated microglia, decreased the levels of amyloid-β, ameliorated impaired long-term object memory, and attenuated decreased synaptophysin, dopamine, brain-derived neurotrophic factor, and insulin-like growth factor 1 levels in the cortex in 5×FAD transgenic mice.

In aged mice fed β-lactolin for 3 months, memory impairment was subsequently alleviated. In aged mice, impairment of light/dark activity cycles was found to be induced, which was subsequently alleviated by β-lactolin consumption.

β-Lactolin, a whey-derived Gly-Thr-Trp-Tyr lactopeptide, activates the dopaminergic system, improves memory impairment, and prevents Alzheimer's pathologies in a rodent model.

Strength of evidence: Animal/in vitro only for Alzheimer's disease pathology. No controlled human trials in Alzheimer's disease populations have been published. These preclinical findings provide mechanistic hypotheses but cannot be extrapolated to humans.

7.4 Mood, Anxiety, and Perceived Stress

Human / Clinical Evidence

A 2024 RCT specifically examined mood outcomes: This randomized, double-blind, placebo-controlled study aimed to evaluate the effects of supplementation with β-lactolin-rich whey peptide on human mood states. Sixty healthy adults (aged 45–64 years) with relatively low psychological health were randomly allocated to receive either whey peptide (containing β-lactolin 1.6 mg/day) or placebo for 6 weeks.

The researchers concluded: "supplementation with β-lactolin improves trait anxiety, subjective stress, and psychological QOL, which may be associated with immunologic responses detected via salivary analysis." Further analysis based on age groups found that reduction in Perceived Stress Scale was more significant in subjects aged 45 to 54 taking β-lactolin. In contrast, in subjects aged 55 to 64, the beneficial effects of β-lactolin on Perceived Stress Scale was not significant.

The antidepressant-like effects observed in animal models are supported by the dopaminergic mechanism: The administration of β-lactolin improved depression-like behavior of rodents, as assessed in the tail suspension test, which was inhibited by the inhibition of dopamine D1-like receptor.

Strength of evidence: Single RCT (n=60) in a specific age/health profile population. Results are suggestive but require independent replication. The stress and anxiety findings in adults aged 55–64 were not significant, suggesting age-dependent effects.

7.5 Prefrontal Cortex Function and Executive Function

Previous studies showed that supplementation with β-lactolin-rich whey peptides improved memory retrieval, attention, and executive function in healthy adults, and the findings suggest that consumption of β-lactolin-rich whey peptides is associated with activation of the frontal cortex, especially the dorsolateral prefrontal cortex regulating memory retrieval and executive function.

In a rodent model specifically studying prefrontal cortex function: The supplementation with a whey digest rich in β-lactolin improves memory retrieval and executive function in a clinical trial, but the effect of β-lactolin on prefrontal cortex (PFC)-associated cognitive function was unclear. Researchers examined the effect of β-lactolin and the whey digest on PFC-associated visual discrimination (VD) and reversal discrimination (RD) learning, using a rodent touch panel-based operant system. β-Lactolin and whey digest may not affect the learning of visual discrimination but may enhance the retrieval or changing of acquired memories. Acquisition of memory is associated with both the PFC and the hippocampus, while memory retrieval is more closely associated with the functioning of the PFC.

8. Dosage Forms and Dosages Reported in Studies

All clinical studies have used oral tablet formulations of GTWY-enriched whey peptide, not isolated β-lactolin. Specific dosages reported are as follows:

• 1.6 mg β-lactolin per day (delivered as a standardized whey peptide tablet) for periods of 6 or 12 weeks: Supplementation with whey peptides richly containing β-lactolin (1.6 mg/day) for 6 and 12 weeks improved memory, attention, and executive functions associated with the function of the dorsolateral prefrontal cortex in middle-aged adults. This dosage was also used in the 2024 anxiety/stress RCT (n=60, aged 45–64 years, 6 weeks): Sixty healthy adults (aged 45–64 years) with relatively low psychological health were randomly allocated to receive either whey peptide (containing β-lactolin 1.6 mg/day) or placebo for 6 weeks.
• 1.8 mg β-lactolin per day for 24 weeks in the MCI trial: Researchers recruited 48 participants aged 50 years or older with a Clinical Dementia Rating (CDR) score of 0.5. Participants were administered β-lactolin (1.8 mg daily) or placebo for 24 weeks.
• The 12-week RCT in 114 healthy adults aged 50–75 used a whey peptide formulation providing β-lactolin assessed at weeks 0, 6, and 12: 114 healthy subjects aged 50–75 were supplemented with the whey peptide or placebo for 12 weeks, and changes in cognitive function were assessed using neuropsychological tests at weeks 0, 6, and 12 of the intervention.
• The cerebral blood flow RCT used 6-week supplementation in 50 healthy participants aged 45–60: Researchers examined the effects of β-lactolin on CBF using near-infrared spectroscopy in a placebo-controlled randomized double-blind study. Fifty healthy participants (45–60 years old) were randomly allocated to the β-lactolin and placebo groups and supplemented for 6 weeks.

It should be noted that the absolute mass of β-lactolin in these studies is very small (approximately 1.6–1.8 mg/day), because the active peptide is delivered embedded within a larger whey peptide matrix in which β-lactolin is enriched but not the sole component.

9. Safety Considerations and Potential Interactions

9.1 Observed Safety Profile in Clinical Trials

In the largest published RCT (n=114): Thirty subjects in the placebo group and 30 subjects in the whey peptide group reported adverse events during the study, but none of these were related to the interventions. Some clinical values changed slightly from baseline, but these were deemed clinically insignificant. Compliance with the supplement was high, with tablet consumption rates close to 100% in both groups. Compliance with interventions was very high, with average tablet consumption rates of 99.9% in the placebo group and 99.8% in the whey peptide group.

9.2 MAO-B Inhibition: Theoretical Interaction Considerations

Because β-lactolin functions as a food-derived MAO-B inhibitor, a theoretical consideration concerns potential interactions with pharmaceutical MAO inhibitors. Classical pharmacological MAO inhibitors — both MAO-A and non-selective — are associated with a serious drug-food interaction known as the "cheese effect": Patients who consume non-selective MAOIs and also consume tyramine-rich foods or drinks (e.g., aged, cured, pickled, smoked, and fermented foods, such as cheese; fermented drinks, such as beer and wine; dried fruit; and fresh citrus) can develop dangerously high serum levels of tyramine. This can result in adverse effects, such as headache, hypertension, gastrointestinal upset, rapid heartbeat, shortness of breath, and neurological problems.

However, the pharmacological MAO inhibitors used clinically (selegiline, rasagiline) are potent irreversible inhibitors, whereas β-lactolin is a food-derived peptide active at microgram concentrations. No published clinical safety study has specifically evaluated β-lactolin in combination with pharmaceutical MAO inhibitors, and the degree of MAO-B inhibition achieved at dietary or supplemental doses has not been quantitatively compared to pharmaceutical MAO inhibitors in humans. The MAO-B selectivity of the peptide — in contrast to MAO-A inhibition — is also relevant to the tyramine pressor response: Tyramine is metabolized by both MAO-A and MAO-B; thus, compounds that selectively inhibit MAO-A but not MAO-B can allow for continued MAO-B-mediated metabolism of tyramine. Nonetheless, the combination of β-lactolin with pharmaceutical MAO inhibitors of any type has not been studied, and caution would be appropriate pending such data.

9.3 Dairy Allergy and Lactose Intolerance

β-Lactolin is derived from β-lactoglobulin, the dominant protein in bovine whey. Individuals with documented cow's milk protein allergy — particularly whey protein allergy — may be at risk of allergic reactions to β-lactolin-containing supplements, as the allergenicity of peptide fragments from β-lactoglobulin is well established. β-Lactoglobulin is absent in human milk but present in bovine milk, and is a major identified allergen in cow's milk allergy.

β-Lactolin itself does not contain lactose (a sugar, not a protein), but commercial whey peptide preparations may contain residual lactose unless specifically processed to remove it.

9.4 Scope of Long-Term Safety Data

There is currently no evidence of the effects of long-term β-lactolin intake on aging in humans. The longest human RCT published used a 24-week intervention in a small sample (n=48). The number of participants was lower than planned, limiting the confirmation of the effectiveness of β-lactolin on MCI. Long-term safety data in humans beyond six months are not available in the peer-reviewed literature.

9.5 Industry Funding and Independence of Evidence

A notable feature of the β-lactolin evidence base is that the preponderance of clinical trials were conducted or funded by Kirin Holdings Co. (Japan). Independent replication by academic groups without industry involvement is not yet documented in the peer-reviewed literature. This does not invalidate the findings but is a relevant consideration for assessing the robustness of the evidence base.

10. Summary of Evidence Strength by Domain

• Cognitive function (memory, attention, executive function) in healthy middle-aged/older adults: Multiple small-to-medium RCTs; integrated analysis shows modest but statistically significant improvement in cued recall (g=0.33). Evidence is promising; independent replication needed.
• Cerebral blood flow and neural activity in humans: Supported by dedicated RCTs using NIRS and EEG. Preliminary; mechanistic studies rather than hard outcome trials.
• Mild cognitive impairment: A single underpowered RCT; primary endpoint not met. Evidence insufficient.
• Alzheimer's disease pathology: Animal models only (5×FAD transgenic mice, PS19 tauopathy mice). No human trials.
• Anxiety, stress, and mood: Single RCT (n=60); positive findings limited to specific age range. Very preliminary.
• Mechanisms of action (MAO-B inhibition, dopamine elevation): Well characterized in rodent models with in vitro corroboration; confirmed to occur in the brain after oral administration in animals.

References

• Ano Y et al. β-Lactolin Reduces Age-Related Inflammation and Cognitive Decline. Frontiers in Nutrition, 2021. PMC8419277
• Ano Y et al. β-Lactolin, a Whey-Derived Lacto-Tetrapeptide, Prevents Alzheimer's Disease Pathologies and Cognitive Decline. Journal of Alzheimer's Disease, 2020. PMC7081097
• Ano Y et al. Supplementation With Whey Peptide Rich in β-Lactolin Improves Cognitive Performance in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study. Frontiers in Neuroscience, 2019. PMC6491855
• Ano Y et al. β-Lactolin, a Whey-Derived Gly-Thr-Trp-Tyr Lactopeptide, Promotes Cerebral Blood Flow During Cognitive Tasks: A Randomized Controlled Trial. PMC8182078
• Kanatome A et al. β-Lactolin Enhances Neural Activity, Indicated by Event-Related P300 Amplitude, in Healthy Adults: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021. PMC8203246
• Effect of Whey-Derived Lactopeptide β-Lactolin on Memory in Healthy Adults: An Integrated Analysis of Data from Randomized Controlled Trials. PMC12878236
• Effects of whey-derived lactopeptide β-Lactolin on cognitive performance in mild cognitive impairment: a randomized, double-blind, placebo-controlled trial. PubMed 39560119
• Ayabe T et al. Supplementation with whey peptide rich in β-lactolin improves trait anxiety and subjective stress in healthy adults: a randomized, double-blind, placebo-controlled study. Scientific Reports, 2024.
• Ayabe T et al. The Lacto-Tetrapeptide Gly–Thr–Trp–Tyr, β-Lactolin, Improves Spatial Memory Functions via Dopamine Release and D1 Receptor Activation in the Hippocampus. Nutrients, 2019.
• β-Lactolin, a Monoamine Oxidase B Inhibitory Lactopeptide, Suppresses Reactive Oxygen Species Production in Lipopolysaccharide-Stimulated Astrocytes. Applied Sciences, 2021.
• Ayabe T, Ohya R, Ano Y. β-Lactolin, a whey-derived glycine–threonine–tryptophan–tyrosine lactotetrapeptide, improves prefrontal cortex-associated reversal learning in mice. Bioscience, Biotechnology, and Biochemistry, 2020.
• Riederer P et al. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 2016. PMC5067815
• Supplementation with whey peptide rich in β-lactolin improves trait anxiety and subjective stress in healthy adults. Scientific Reports, 2024. PMC11461648